Emerging studies suggest this peptide, a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to represent a promising advancement for obesity treatment. Early patient trials have demonstrated impressive decreases in visceral fat , conceivably surpassing current obesity treatments. However , additional